Nemaura Medical (NMRD) 10-Q 11 Sep 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	8 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Document and Entity Information:	'	'
Entity Registrant Name	'Nemaura Medical Inc.	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Entity Central Index Key	'0001602078	'
Current Fiscal Year End Date	'--10-31	'
Entity Common Stock, Shares Outstanding	'	200,000,000
Entity Public Float	$1,286,353	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Statement_of_Financial_Positio

Statement of Financial Position (USD $)	Jun. 30, 2014	Mar. 31, 2014
Assets, Current	'	'
Cash and Cash Equivalents, at Carrying Value	$1,111,694	$1,873,141
Restricrted Cash, Current	94,917	'
Prepayments and Other Assets	64,909	20,390
Prepayment to Related Party for clinical trials	561,132	'
Assets, Current	1,832,652	1,893,531
Assets, Noncurrent	'	'
Finite-Lived Intangible Assets, Net	71,624	70,781
Restricted Cash, Noncurrent	'	85,462
Assets, Noncurrent	71,624	156,243
Assets	1,904,276	2,049,774
Liabilities, Current	'	'
Accounts Payable, Current	105,461	1,830
Other Liabilities, Current	10,376	6,844
Liabilities, Current	115,837	8,674
Liabilities, Noncurrent	'	'
Deferred Revenue and Credits, Noncurrent	1,687,800	1,667,200
Liabilities, Noncurrent	1,687,800	1,667,200
Liabilities	1,803,637	1,675,874
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	'	'
Common Stock, Value, Issued	200,000	200,000
Additional Paid in Capital, Common Stock	2,924,672	2,924,672
Accumulated Other Comprehensive Income (Loss), Net of Tax	-12,893	-8,882
Retained Earnings (Accumulated Deficit)	-3,011,140	-2,741,890
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	100,639	373,900
Liabilities and Equity	$1,904,276	$2,049,774

Statement_of_Financial_Positio1

Statement of Financial Position - Parenthetical (USD $)	Jun. 30, 2014	Mar. 31, 2014
Balance Sheets	'	'
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	420,000,000	420,000,000
Common Stock, Shares Issued	200,000,000	200,000,000
Common Stock, Shares Outstanding	200,000,000	200,000,000

Statement_of_Income

Statement of Income (USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating Expenses	'	'
Research and Development Expense	$162,486	$59,752
General and Administrative Expense	106,764	2,026
Operating Expenses	269,250	61,778
Operating Income (Loss)	-269,250	-61,778
Net Income (Loss)	-269,250	-61,778
Foreign Currency Transaction Adjustment	-4,011	-2,224
Comprehensive Income (Loss)	($273,261)	($64,002)
Earnings Per Share	'	'
Earnings Per Share, Basic	$0	$0
Weighted Average Number of Shares Outstanding, Basic	200,000,000	200,000,000

Statement_of_Cash_Flows

Statement of Cash Flows (USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Net Cash Provided by (Used in) Operating Activities	'	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	($269,250)	($61,778)
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	'	'
Depreciation and Amortization	1,404	721
Other Cost of Services	'	-96,579
Increase (Decrease) in Assets and Liabilities	'	'
Increase (Decrease) in Receivables	-44,015	-15,194
Increase (Decrease) in Prepaid Expense and Other Assets	-561,132	'
Increase (Decrease) in Accounts Payable	106,781	'
Net Cash Provided by (Used in) Operating Activities	-766,212	-172,830
Net Cash Provided by (Used in) Investing Activities	'	'
Increase Decrease In Restricted Cash And Investments	-9,455	'
Purchase of Intellectual Property	-1,373	-8,848
Net Cash Provided by (Used in) Investing Activities	-10,828	-8,848
Cash and Cash Equivalents, Period Increase (Decrease)	-777,041	-181,678
Effect of Exchange Rate Changes on Cash	15,593	-1,365
Cash and Cash Equivalents, at Carrying Value	1,873,141	200,485
Cash and Cash Equivalents, at Carrying Value	$1,111,694	$17,442

Note_1_Organization_and_Princi

Note 1 - Organization and Principal Activities	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 1 - Organization and Principal Activities	'
	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES
	Nemaura Medical Inc. (“Nemaura” or the “Company”), through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (“CGM”). The CGM system is a non-invasive, wireless continuous glucose monitoring device for use by persons with Type I and Type II diabetes, and also for screening pre-diabetic patients. The CGM allows for the extraction of analytes, such as glucose, in a non-invasive manner to the surface of the skin where it is measured using unique sensors and interpreted using a unique algorithm.
	Nemaura is a holding corporation that owns one hundred percent (100%) of a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices, and was organized on December 24, 2013 under the laws of the State of Nevada.   Nemaura owns one hundred percent (100%) of Region Green Limited, a British Virgin Islands corporation formed on December 12, 2013.  Region Green Limited owns one hundred percent (100%) of the stock in Dermal Diagnostic (Holdings) Limited, an England and Wales corporation formed on December 11, 2013, which in turn owns one hundred percent (100%) of Dermal Diagnostics Limited, an England and Wales corporation formed on January 20, 2009 (“DDL”), and one hundred percent (100%) of Trial Clinic Limited, an England and Wales corporation formed on January 12, 2011 (“TCL”).
	DDL is a diagnostic medical device company headquartered in Loughborough, Leicestershire, England, and is engaged in the discovery, development and commercialization of diagnostic medical devices. The Company’s initial focus has been on the development of the CGM device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source, which can enable early detection of subtle changes in blood glucose levels.

Note_2_Basis_of_Presentation

Note 2 -- Basis of Presentation	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 2 -- Basis of Presentation	'
	NOTE 2 -- BASIS OF PRESENTATION
	The accompanying financial statements of Nemaura have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at June 30, 2014 and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company’s Registration Statement on Form S-1 filed with the Securities Exchange Commission on August 12, 2014. The results of operations for the period ended June 30, 2014 are not necessarily an indication of operating results for the full year.
	In the quarter ending June 30, 2014, the Company elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU has allowed the Company to remove the inception to date information and all references to development stage.
	The functional currency for the majority of the Company’s operations is the Great Britain Pound Sterling (“GBP”), and the reporting currency is the US Dollar.

Note_3_Summary_of_Significant_

Note 3 - Summary of Significant Accounting Policies	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 3 - Summary of Significant Accounting Policies	'
	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a)  Economic and political risk
	The Company’s operations are conducted in United Kingdom. Accordingly, the political, economic, and legal environments in the United Kingdom may influence the Company’s business, financial condition, and results of operations.
	(b) Cash and Restricted Cash
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.  Cash and cash equivalents consist primarily of cash deposits maintained in the United Kingdom. From time to time, the Company’s cash account balances exceed amounts covered by the Financial Services Compensation Scheme. The Company has never suffered a loss due to such excess balances. The Company’s restricted cash includes cash held in escrow with use restricted to certain future listing costs.
	(c)  Fair value of financial instruments
	The Company’s financial instruments primarily consist of cash and restricted cash and accounts payable. As of the period-end dates, the estimated fair values of financial instruments were not materially different from their carrying values as presented, due to their short maturities.
	(d) Intangible assets
	Intangible assets consist of licenses and patents associated with the CGM and are amortized on a straight-line basis, generally over their legal life.
	(e)  Revenue Recognition
	Revenue is recognized when the four basic criteria of revenue recognition are met:  (1) a contractual agreement exists; (2) transfer of rights has been completed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
	The Company may enter into product development and other agreements with collaborative partners. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations.
	The Company recognizes up front license payments as revenue upon delivery of the license only if the license has standalone value to the customer. However, where further performance criteria must be met, revenue is deferred and recognized on a straight line basis over the period the Company is expected to complete its performance obligations.
	Royalty revenue will be recognized upon the sale of the related products provided the Company has no remaining performance obligations under the agreement.
	(f)  Research and Development Expenses
	The Company charges research and development expenses to operations as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel and outside contractor and consulting services. Other research and development expenses include the costs of materials and supplies used in research and development, prototype manufacturing, clinical studies, related information technology and an allocation of facilities costs.
	(g)            Income taxes
	Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to reduce the carrying amount of deferred income tax assets if it is considered more likely than not that some portion, or all, of the deferred income tax assets will not be realized.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits as part of income tax expense in the Consolidated Statements of Comprehensive Income (Loss).
	(h)            Earnings per share
	Basic earnings per share is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding during the period. There were no potentially dilutive securities as of June 30, 2014 and 2013. For the three months ended June 30, 2013 the ordinary shares outstanding have been retroactively adjusted to reflect the December 24, 2013 recapitalization.
	(i)             Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results may differ from those estimates.
	(j)             Foreign currency translation
	The functional currency of the Company is the Great Britain Pound Sterling (“GBP”).  The reporting currency is the United States dollar (US$).  Stockholders’ equity is translated into United States dollars from GBP at historical exchange rates.  Assets and liabilities are translated at the exchange rates as of balance sheet date. Income and expenditures are translated at the average exchange rates prevailing during the reporting period.
	The translation rates are as follows:
		June 30,	June 30,	March 31,
		2014	2013	2014
		(unaudited)	(unaudited)
	Period end GBP : US$ exchange rate	1.688	1.504	1.667
	Average period/yearly GBP : US$ exchange rate	1.676	1.514	1.588
	Adjustments resulting from translating the financial statements into the United States dollar are recorded as a separate component of accumulated other comprehensive income in Stockholders’ Equity.
	(k)            Recent accounting pronouncements
	The Company has evaluated all of the newly issued accounting pronouncements and believes such pronouncements do not have a material effect on the Company’s condensed consolidated financial statements.

Note_4_Licensing_Agreement

Note 4 - Licensing Agreement	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 4 - Licensing Agreement	'
	NOTE 4 – LICENSING AGREEMENT
	In March 2014, the Company entered into an Exclusive Marketing Rights Agreement with an unrelated third party that granted to the third party the exclusive right to market and promote the CGM and related patches under its own brand in the United Kingdom and the Republic of Ireland. The Company received a non-refundable, upfront cash payment of GBP 1,000,000 (approximately $1,690,000),which is wholly non-refundable, upon signing the agreement. A supply cost for goods agreement will be finalized upon product approval and prior to launch, as part of the full commercial licensing agreement also to be signed closer to product approval and launch.
	As the Company has continuing performance obligations under the agreement, the upfront fees received from this agreement have been deferred and will be recorded as income over the term of the commercial licensing agreement.
	In April 2014, a Letter of Intent was signed with the third party, which specified a 10 year term.

Note_5_Cash_and_Restricted_Cas

Note 5 - Cash and Restricted Cash	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 5 - Cash and Restricted Cash	'
	NOTE 5 – CASH AND RESTRICTED CASH
	As of June 30, 2014 and March 31, 2014, the Company held $1,111,694 and $1,873,141 in cash, respectively. At June 30, 2014, funds were also held in a restricted escrow account of $94,917, with use restricted to certain future listing costs.

Note_6_Intangible_Assets

Note 6 - Intangible Assets	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 6 - Intangible Assets	'
	NOTE 6 – INTANGIBLE ASSETS
	Intangible assets are summarized as follows:
		June 30,	March 31,
		2014	2014
		(unaudited)
		($)	($)
	Patents and licenses	84,954	87,655
	Less accumulated amortization	-13,330	-16,874
		71,624	70,781
	Estimated amortization expense is approximately $5,600 for each of the next five years.

Note_7_Related_Party_Transacti

Note 7 - Related Party Transactions	8 Months Ended
	Jun. 30, 2014
Notes	'
Note 7 - Related Party Transactions	'
	NOTE 7 – RELATED PARTY TRANSACTIONS
	Nemaura Pharma Limited (Pharma) and NDM Technologies Limited (NDM) are entities controlled by the Company’s majority shareholder DFH Chowdhury.
	From inception, Pharma invoiced DDL and TCL for research and development services. In addition, certain operating expenses of DDL and TCL were incurred and paid by Pharma and NDM. In accordance with the United States Securities and Exchange Commission (SEC) Staff Accounting Bulletin 55, these financial statements reflect all costs associated with the operations of DDL and TCL. While certain costs incurred by Pharma and NDM are directly attributable to DDL and TCL, other costs were shared between the organizations. In situations where the costs were shared, expense has been allocated between Pharma and NDM and DDL and TCL using a fixed percentage allocation. Management believes the methodologies used are reasonable and that the costs allocated are not materially different from what they would have been had Pharma and NDM been unaffiliated entities. DDL and TCL advanced Pharma certain amounts to cover a portion of the costs. The remaining amounts were contributed to the Company in the form of contributed services.
	Following is a summary of activity between the Company and Pharma and NDM as of June 30, 2014 (unaudited) and March 31, 2014:
		Three Months Ended	Year Ended
		June 30,2014	31-Mar-14
		($)	($)
	Balance due (to) Pharma and NDM at beginning of period	-	-
	Amounts advanced to Pharma	596,848	325,092
	Amounts received from Pharma	-1,676	-149,280
	Amounts invoiced by Pharma to DDL and TCL	-32,685	-557,670
	Expenses paid by Pharma on behalf of DDL and TCL	-	-28,574
	Assets contributed by Pharma on behalf of DDL and TCL	-	-7,327
	Capital contribution by Pharma (excess of expenses paid over amounts advanced)	-	420,401
	Foreign exchange differences	-1,355	-2,642
	Balance due from (to) Pharma and NDM at end of the period	561,132	-
	Advances to Pharma as of June 30, 2014 consist of amounts advanced in connection with the Company’s planned clinical trials. These advances are expected to be expensed in the third and fourth quarters of fiscal 2015, as clinical trials commence.

Note_3_Summary_of_Significant_1

Note 3 - Summary of Significant Accounting Policies: Economic and Political Risk (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Economic and Political Risk	'
	(a)  Economic and political risk
	The Company’s operations are conducted in United Kingdom. Accordingly, the political, economic, and legal environments in the United Kingdom may influence the Company’s business, financial condition, and results of operations.

Note_3_Summary_of_Significant_2

Note 3 - Summary of Significant Accounting Policies: Cash and Restricted Cash (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Cash and Restricted Cash	'
	(b) Cash and Restricted Cash
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.  Cash and cash equivalents consist primarily of cash deposits maintained in the United Kingdom. From time to time, the Company’s cash account balances exceed amounts covered by the Financial Services Compensation Scheme. The Company has never suffered a loss due to such excess balances. The Company’s restricted cash includes cash held in escrow with use restricted to certain future listing costs.

Note_3_Summary_of_Significant_3

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Fair Value of Financial Instruments	'
	(c)  Fair value of financial instruments
	The Company’s financial instruments primarily consist of cash and restricted cash and accounts payable. As of the period-end dates, the estimated fair values of financial instruments were not materially different from their carrying values as presented, due to their short maturities.

Note_3_Summary_of_Significant_4

Note 3 - Summary of Significant Accounting Policies: Intangible Assets (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Intangible Assets	'
	(d) Intangible assets
	Intangible assets consist of licenses and patents associated with the CGM and are amortized on a straight-line basis, generally over their legal life.

Note_3_Summary_of_Significant_5

Note 3 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Revenue Recognition	'
	(e)  Revenue Recognition
	Revenue is recognized when the four basic criteria of revenue recognition are met:  (1) a contractual agreement exists; (2) transfer of rights has been completed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
	The Company may enter into product development and other agreements with collaborative partners. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations.
	The Company recognizes up front license payments as revenue upon delivery of the license only if the license has standalone value to the customer. However, where further performance criteria must be met, revenue is deferred and recognized on a straight line basis over the period the Company is expected to complete its performance obligations.
	Royalty revenue will be recognized upon the sale of the related products provided the Company has no remaining performance obligations under the agreement.

Note_3_Summary_of_Significant_6

Note 3 - Summary of Significant Accounting Policies: Research and Development Expenses (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Research and Development Expenses	'
	(f)  Research and Development Expenses
	The Company charges research and development expenses to operations as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel and outside contractor and consulting services. Other research and development expenses include the costs of materials and supplies used in research and development, prototype manufacturing, clinical studies, related information technology and an allocation of facilities costs.

Note_3_Summary_of_Significant_7

Note 3 - Summary of Significant Accounting Policies: Income Taxes (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Income Taxes	'
	(g)            Income taxes
	Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to reduce the carrying amount of deferred income tax assets if it is considered more likely than not that some portion, or all, of the deferred income tax assets will not be realized.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits as part of income tax expense in the Consolidated Statements of Comprehensive Income (Loss).

Note_3_Summary_of_Significant_8

Note 3 - Summary of Significant Accounting Policies: Earnings Per Share (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Earnings Per Share	'
	(h)            Earnings per share
	Basic earnings per share is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding during the period. There were no potentially dilutive securities as of June 30, 2014 and 2013. For the three months ended June 30, 2013 the ordinary shares outstanding have been retroactively adjusted to reflect the December 24, 2013 recapitalization.

Note_3_Summary_of_Significant_9

Note 3 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Use of Estimates	'
	(i)             Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results may differ from those estimates.

Recovered_Sheet1

Note 3 - Summary of Significant Accounting Policies: Foreign Currency Translation (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Foreign Currency Translation	'
	(j)             Foreign currency translation
	The functional currency of the Company is the Great Britain Pound Sterling (“GBP”).  The reporting currency is the United States dollar (US$).  Stockholders’ equity is translated into United States dollars from GBP at historical exchange rates.  Assets and liabilities are translated at the exchange rates as of balance sheet date. Income and expenditures are translated at the average exchange rates prevailing during the reporting period.
	The translation rates are as follows:
		June 30,	June 30,	March 31,
		2014	2013	2014
		(unaudited)	(unaudited)
	Period end GBP : US$ exchange rate	1.688	1.504	1.667
	Average period/yearly GBP : US$ exchange rate	1.676	1.514	1.588
	Adjustments resulting from translating the financial statements into the United States dollar are recorded as a separate component of accumulated other comprehensive income in Stockholders’ Equity.

Recovered_Sheet2

Note 3 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	8 Months Ended
	Jun. 30, 2014
Policies	'
Recent Accounting Pronouncements	'
	(k)            Recent accounting pronouncements
	The Company has evaluated all of the newly issued accounting pronouncements and believes such pronouncements do not have a material effect on the Company’s condensed consolidated financial statements.

Recovered_Sheet3

Note 3 - Summary of Significant Accounting Policies: Foreign Currency Translation: Foreign Currency Disclosure (Tables)	8 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Foreign Currency Disclosure	'
		June 30,	June 30,	March 31,
		2014	2013	2014
		(unaudited)	(unaudited)
	Period end GBP : US$ exchange rate	1.688	1.504	1.667
	Average period/yearly GBP : US$ exchange rate	1.676	1.514	1.588

Note_6_Intangible_Assets_Sched

Note 6 - Intangible Assets: Schedule of Finite-Lived Intangible Assets (Tables)	8 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Finite-Lived Intangible Assets	'
		June 30,	March 31,
		2014	2014
		(unaudited)
		($)	($)
	Patents and licenses	84,954	87,655
	Less accumulated amortization	-13,330	-16,874
		71,624	70,781

Note_7_Related_Party_Transacti1

Note 7 - Related Party Transactions: Schedule of Related Party Transactions (Tables)	8 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Related Party Transactions	'
		Three Months Ended	Year Ended
		June 30,2014	31-Mar-14
		($)	($)
	Balance due (to) Pharma and NDM at beginning of period	-	-
	Amounts advanced to Pharma	596,848	325,092
	Amounts received from Pharma	-1,676	-149,280
	Amounts invoiced by Pharma to DDL and TCL	-32,685	-557,670
	Expenses paid by Pharma on behalf of DDL and TCL	-	-28,574
	Assets contributed by Pharma on behalf of DDL and TCL	-	-7,327
	Capital contribution by Pharma (excess of expenses paid over amounts advanced)	-	420,401
	Foreign exchange differences	-1,355	-2,642
	Balance due from (to) Pharma and NDM at end of the period	561,132	-

Note_4_Licensing_Agreement_Det

Note 4 - Licensing Agreement (Details) (USD $)	0 Months Ended
	Mar. 31, 2014
Details	'
Licensing Agreement	$1,690,000	[1]
[1]	A non-refundable, upfront cash payment, which is wholly non-refundable, upon signing the agreement